Annovis Bio 주식 가격. ANVS - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

개인 투자자를 위한 전문가급 도구.

프리미엄

가격

28.23

매수가

매도가

거래량

0.00 일간 변동폭 0.00

0.00 52주 범위 0.00

market_cap

289.696M

전일 종가

28.23

개장가

최근 거래 시간

마지막 거래 시간

재정 규모

VWAP

평균 볼륨(3m)

발행 주식

10,262,000

배당수익률

주가수익률

-0.98

주당순이익(EPS)

-5.48

매출

순이익

-56.2M

Annovis Bio Inc is a clinical stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neuro degenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301. Annovis Bio Inc is a clinical stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neuro degenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.

섹터

Pharmaceutical Preparations

산업

Pharmaceutical Preparations

웹사이트

www.annovisbio.com

본부

Dover, Delaware, USA

설립됨

Annovis to Host Year-End Investor Webcast on December 11, 2024

MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is...

Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)

MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative...

Annovis Bio Reports Third Quarter Financial Results and Provides Business Update

MALVERN, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for...

Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist

MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative...

Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024

MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative...

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs

MALVERN, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative...

Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases

NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Annovis Bio Inc. (NYSE: ANVS) announces the availability of a broadcast titled, “Transforming Alzheimer’s Treatment: Innovative...

Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations

NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via InvestorWire — Annovis Bio Inc. (NYSE: ANVS) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands...

Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra

MALVERN, Pa., Sept. 30, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative...

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference

MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing novel therapies for...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

ANVS - Frequently Asked Questions (FAQ)

What is the current Annovis Bio share price?

The current share price of Annovis Bio is US$ 28.23

How many Annovis Bio shares are in issue?

Annovis Bio has 10,262,000 shares in issue

What is the market cap of Annovis Bio?

The market capitalisation of Annovis Bio is USD 289.7M

What is the 1 year trading range for Annovis Bio share price?

Annovis Bio has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the PE ratio of Annovis Bio?

The price to earnings ratio of Annovis Bio is -0.98

What is the reporting currency for Annovis Bio?

Annovis Bio reports financial results in USD

What is the latest annual profit for Annovis Bio?

The latest annual profit of Annovis Bio is USD -56.2M

What is the registered address of Annovis Bio?

The registered address for Annovis Bio is 1111B S GOVERNORS AVENUE, KENT, DOVER, DELAWARE, 19904

What is the Annovis Bio website address?

The website address for Annovis Bio is www.annovisbio.com

Which industry sector does Annovis Bio operate in?

Annovis Bio operates in the PHARMACEUTICAL PREPARATIONS sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
RHERegional Health Properties Inc	US$ 3.42 (120.65%)	41.37M
OPTTOcean Power Technologies Inc	US$ 1.6006 (44.20%)	80.84M
MITQMoving iMage Technologies Inc	US$ 0.8502 (33.32%)	1.07M
ATCHAtlasClear Holdings Inc	US$ 10.75 (31.90%)	181.93k
CPHIChina Pharma Holdings Inc	US$ 0.2899 (25.93%)	12.57M
AEONAEON Biopharma Inc	US$ 0.2045 (-64.06%)	95.85M
MSTZT Rex 2X Inverse MSTR Daily Target ETF	US$ 14.72 (-23.37%)	23.92M
ITPIT Tech Packaging Inc	US$ 0.427 (-17.57%)	959.59k
KNWKnow Labs Inc	US$ 0.1558 (-15.69%)	3.46M
AMBOAmbow Education Holding Ltd	US$ 2.40 (-13.98%)	46.51k
JOBGEE Group Inc	US$ 0.2652 (22.21%)	191.18M
AEONAEON Biopharma Inc	US$ 0.2045 (-64.06%)	95.85M
SOXLDirexion Daily Semiconductor Bull 3X Shares	US$ 32.49 (8.95%)	94.47M
SPXSDirexion Daily S&P 500 Bear 3X Shares New	US$ 6.00 (-1.64%)	87.6M
OPTTOcean Power Technologies Inc	US$ 1.6006 (44.20%)	80.84M